协和医学杂志2025，Vol.16Issue(6)：1357-1362,6.DOI:10.12290/xhyxzz.2025-0757
免疫介导的炎症性疾病治疗药物相关肿瘤风险与管理策略
Tumor Risk and Management Strategies Associated with Therapeutic Agents for Immune-Mediated Inflammatory Diseases
摘要
Abstract
Immune-mediated inflammatory diseases(IMIDs)represent a heterogeneous group of disorders characterized by chronic inflammation.Their long disease duration and relapsing nature often necessi-tate long-term,sometimes lifelong,pharmacotherapy.However,the adverse effects associated with these medi-cations cannot be overlooked,with particular attention warranted for the potential risk of malignancy.This article reviews the current evidence regarding the oncogenic risk of major therapeutic agents used for IMIDs,ai-ming to enhance clinicians'comprehensive understanding of these drugs.For IMIDs patients with a history of malignancy or those possessing other risk factors for cancer,this knowledge may encourage more deliberate de-liberation and a more thorough assessment when selecting appropriate treatment options,thereby facilitating bet-ter management of drug-associated malignancy risks.关键词
免疫介导的炎症性疾病/药物安全性/肿瘤风险Key words
immune-mediated inflammatory diseases/drug safety/cancer risk分类
医药卫生引用本文复制引用
魏宇歌,杨红,钱家鸣..免疫介导的炎症性疾病治疗药物相关肿瘤风险与管理策略[J].协和医学杂志,2025,16(6):1357-1362,6.基金项目
National Key Research and Development Program of China(2023YFC2507302) （2023YFC2507302）
Beijing Natural Science Founda-tion(7252113) （7252113）
National Natural Science Foundation of China(82570621) 国家重点研发计划(2023YFC2507302) （82570621）
北京市自然科学基金(7252113) （7252113）
国家自然科学基金(82570621) （82570621）
